LYTACs (Lysosome Targeting Chimeras) are a revolutionary biotechnology designed to facilitate the targeted degradation of cell surface proteins by promoting their binding with lysosomal receptors. This technique combines antibodies or ligands that specifically recognize target proteins with linkers capable of directing these proteins to lysosomes for degradation. The development of LYTACs offers a new strategy for treating various diseases, including cancer and autoimmune diseases. Currently, this technology is still in the research phase, and its efficacy and safety require further validation and optimization.